

Clinical Trials of Parkinson’s Disease Drug Therapies

Trial Change in Status* Dashboard: Q1 2023

*Registered, Started or Finished Recruiting, Completed
 posted on ClinicalTrials.gov between Jan. 1, 2023, and Mar. 31, 2023

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Prior Status	New Status
NCT04658186	UCB0599	UCB and Neuropore (NPT 200-11)	Inhibitor of aSN misfolding	Phase 2	A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease	450	Recruiting	Active, not recruiting
NCT04651153	UCB7853	UCB and Neuropore	aSN antibody	Phase 1	A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)	57	Recruiting	Active, not recruiting
NCT04167540	AAV2-GDNF	Bayer (was Ask Bio)	GDNF gene therapy	Phase 1	GDNF Gene Therapy for Parkinson's Disease	11	Recruiting	Active, not recruiting
NCT03968133	Ecologic BARRIER 849 (Probiotic)	British Columbia University	Probiotic	Phase 2	Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic	61	Recruiting	Active, not recruiting
NCT03683225	CTC-413	Chase Therapeutics	Extended-release pramipexole	Phase 2	A Study to Evaluate in Patients With Parkinsonian Type Disorders	24	Unknown status	Active, not recruiting
NCT03667404	Resistant maltodextrin	Northwestern University	Prebiotic non-digestible fiber	Phase 2	Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study	30	Recruiting	Active, not recruiting
NCT05699161	Adipose-derived Stromal Vascular Fraction Cells	National Autonomous University of Nicaragua	Autologous adipose tissue-derived stromal vascular fraction (SVF) cells	Phase 1 Phase 2	Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson	10	Not in CT.GOV	Completed
NCT05148884	NLX-112 (befiradol)	Neurolixis	Selective serotonin 5-HT1A full agonist	Phase 2	Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia	27	Recruiting	Completed
NCT05083260	NE3107	Biovie	Reduces neuroinflammation and insulin resistance	Phase 1 Phase 2	NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa	46	Active, not recruiting	Completed

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Prior Status	New Status
NCT04350177	iKT-148009	Inhibikase Therapeutics	c-Abl kinase inhibitor	Phase 1	A Study to Assess Single and Multiple Doses of IKT-148009 in Healthy Elderly Participants and Parkinson's Patients	101	Active, not recruiting	Completed
NCT04334317	TAK-071	Takeda	M1 positive allosteric modulator	Phase 2	A Study of TAK-071 in People With Parkinson Disease	64	Active, not recruiting	Completed
NCT04165837	FB-101/1ST-102	1st Biotherapeutics	c-Abl kinase inhibitor	Phase 1	Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects	24	Active, not recruiting	Completed
NCT04075318	UB-312	Vaxxinity (was United Neuroscience)	"Endobody" to aSN	Phase 1	Study of UB-312 in Healthy Participants and Parkinson's Disease Patients	138	Active, not recruiting	Completed
NCT04074837	NNI-362	Neuronascent	Neurorestorative	Phase 1	Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers	56	Unknown status	Completed
NCT03329508	P2B001	Pharma Two B	Rasagiline/pramipexole combination	Phase 3	A Phase 3 Study With P2B001 in Subjects With Early Parkinson's	544	Active, not recruiting	Completed
NCT05790382	NM-101	Neuramedy Co. Ltd.	Anti-TLR2 antibody	Phase 1	Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101	56	Not in CT.GOV	Not yet recruiting
NCT05781711	Metformin	Tanta University	Biguanide antidiabetic (increases insulin sensitivity)	Phase 2	Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease	60	Not in CT.GOV	Not yet recruiting
NCT05778695	KetoneAid	University of Michigan	Ketone ester (KE) dietary supplement	Phase 1	Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones	30	Not in CT.GOV	Not yet recruiting
NCT05778617	Ambroxol	Lawson Health Research Institute	Cough medicine, Gcase enhancer	Phase 3	Ambroxol to Slow Progression in Parkinson Disease	330	Not in CT.GOV	Not yet recruiting
NCT05709301	Donepezil	Oregon Health & Science University	Cholinesterase inhibitor	Phase 2	Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease	120	Not in CT.GOV	Not yet recruiting
NCT05677633	Leukine (sargramostim)	Nebraska University	Recombinant GM-CSF	Phase 1	Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease	10	Not in CT.GOV	Not yet recruiting
NCT05766813	ITI-214 (lenrispodun)	Intra-cellular Therapies	PDE-1 inhibitor	Phase 2	Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease	132	Not in CT.GOV	Recruiting
NCT05691114	Human Amniotic Epithelial Stem Cells	Shanghai iCELL Biotechnology Co., Ltd	Human Amniotic Epithelial Stem Cells	Phase 1	Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson's Disease	18	Not in CT.GOV	Recruiting

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Prior Status	New Status
NCT05670782	KM819	Kainos Medicine	FAF 1 inhibitor	Phase 2	A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease	330	Not in CT.GOV	Recruiting
NCT04220762	WIN-1001X	Medi Help Line	Herbal mixture	Phase 2	A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients	188	Recruiting	Unknown status
NCT04146519	Autologous Mesenchymal stem cells	Belarussian Medical Academy	Mesenchymal stem cells	Phase 2 Phase 3	Parkinson's Disease Therapy Using Cell Technology	50	Recruiting	Unknown status
NCT04097080	NBTX-001	Nobilis Therapeutics	Inhaled xenon	Phase 1	Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease	60	Recruiting	Unknown status